How many insider trades does FilingIQ track for VTVT?

FilingIQ tracks 97 Form 4 insider transactions for VTVT (vTv Therapeutics Inc.), covering filings from Aug 7, 2015 onwards. 2 of those were filed in the last 90 days.

Are VTVT insiders net buyers or net sellers?

Across the full Form 4 history for VTVT, 71 transactions (73%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does VTVT insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is VTVT in?

vTv Therapeutics Inc. (VTVT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $139.56M.

VTVT insider trading

NasdaqCM Healthcare

vTv Therapeutics Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

73% / 1%

Market cap

$139.56M

About vTv Therapeutics Inc.

vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. The company was incorporated in 2015 and is headquartered in High Point, North Carolina.

Company website: vtvtherapeutics.com

VTVT insider activity at a glance

FilingIQ has scored 97 insider transactions for VTVT since Aug 7, 2015. The most recent filing in our index is dated Feb 17, 2026.

Across the full history, 71 open-market purchases and 1 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on VTVT insider trades is 59.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live VTVT trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for VTVT?: FilingIQ tracks 97 Form 4 insider transactions for VTVT (vTv Therapeutics Inc.), covering filings from Aug 7, 2015 onwards. 2 of those were filed in the last 90 days.
Are VTVT insiders net buyers or net sellers?: Across the full Form 4 history for VTVT, 71 transactions (73%) were open-market purchases and 1 (1%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does VTVT insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is VTVT in?: vTv Therapeutics Inc. (VTVT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $139.56M.

Methodology & sources

Every VTVT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.